Filing Overview
Invivyd, Inc. filed a Form 8-K dated September 9, 2022, reporting a corporate name change. The company was formerly named Adagio Therapeutics, Inc.
Business Context and Reporting Period
On September 9, 2022, the company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State. The name change became effective September 13, 2022.
Material Corporate Changes
- The legal name changed from “Adagio Therapeutics, Inc.” to “Invivyd, Inc.”
- The company’s bylaws were amended solely to reflect the new name; no other bylaw changes were reported.
- The common stock ticker changed from “ADGI” to “IVVD,” effective September 13, 2022.
- The common stock continued trading on Nasdaq, and the CUSIP remained 00534A102.
- The company stated that the name change did not affect the rights of security holders.
Financial Metrics, Liquidity, and Outlook
The filing does not provide financial statements, revenue, profit, cash flow, margin, debt, liquidity, guidance, or operating outlook information.
Risks, Contingencies, and Unusual Items
No material risks, contingencies, or unusual financial items were disclosed in the provided filing text. The principal reported event was the corporate name and ticker-symbol change.
Investor Verification Items
- Verify the effective date of the legal name and ticker changes: September 13, 2022.
- Confirm continued Nasdaq listing and the new ticker symbol, IVVD.
- Review Exhibits 3.1 and 3.2 for the certificate amendment and amended bylaws.
- Use separate periodic filings to assess the company’s financial condition, operating performance, and liquidity, as this 8-K contains no financial metrics.